Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

Cancer Immunology, Immunotherapy

Volumn 60, Issue 6, 2011, Pages 757-769

  Smits, Evelien L J ^a   Lee, Cindy ^b,c   Hardwick, Nicola ^d   Brooks, Suzanne ^c   Van Tendeloo, Viggo F I ^a   Orchard, Kim ^b   Guinn, Barbara Ann ^c,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute leukaemia; Adoptive transfer; AML; Cellular therapy; Immunotherapy; Whole cell vaccine

Indexed keywords

BCG VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; INTERLEUKIN 6; IPILIMUMAB; LEUKEMIA ANTIGEN; MITOMYCIN C;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CELL THERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; LEUKEMIA RELAPSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR CELL; VACCINATION;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOID, ACUTE;

EID: 79959709351     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1022-6     Document Type: Review

References (186)

1. JE Rubnitz B Gibson FO Smith 2010 Acute myeloid leukemia Hematol Oncol Clin North Am 24 35 63
2. Stone RM, O'Donnell MR, Sekeres MA (2004) Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 98-117
3. MR O'Donnell CN Abboud J Altman, et al. 2010 Acute myeloid leukemia J Natl Compr Canc Netw 9 280 317
4. M Hamadani FT Awan P Elder, et al. 2008 Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect Biol Blood Marrow Transplant 14 480 483 (Pubitemid 351372744)
5. RJ Soiffer 2008 Donor lymphocyte infusions for acute myeloid leukaemia Best Pract Res Clin Haematol 21 455 466
6. M Hamadani FT Awan EA Copelan 2008 Hematopoietic stem cell transplantation in adults with acute myeloid leukemia Biol Blood Marrow Transplant 14 556 567 (Pubitemid 351505928)
7. T Lodewyck JJ Cornelissen 2008 Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach Blood Rev 22 293 302
8. R Storb 2009 Reduced-intensity conditioning transplantation in myeloid malignancies Curr Opin Oncol 21 S3 S5
9. AM Marmont MM Horowitz RP Gale, et al. 1991 T-cell depletion of HLA-identical transplants in leukemia Blood 78 2120 2130
10. PV O'Donnell L Luznik RJ Jones, et al. 2002 Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide Biol Blood Marrow Transplant 8 377 386
11. L Luznik J Bolanos-Meade M Zahurak, et al. 2010 High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease Blood 115 3224 3230
12. L Luznik PV O'Donnell HJ Symons, et al. 2008 HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 641 650 (Pubitemid 351664058)
13. K Rezvani AJ Barrett 2008 Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation Best Pract Res Clin Haematol 21 437 453
14. EL Smits ZN Berneman VF Van Tendeloo 2009 Immunotherapy of acute myeloid leukemia: current approaches Oncologist 14 240 252
15. M Schmitt R Casalegno-Garduno X Xu, et al. 2009 Peptide vaccines for patients with acute myeloid leukemia Expert Rev Vaccines 8 1415 1425
16. AJ Barrett K Le Blanc 2010 Immunotherapy prospects for acute myeloid leukaemia Clin Exp Immunol 161 223 232
17. K Liseth E Ersvaer T Hervig, et al. 2010 Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience J Biomed Biotechnol 2010 692097
18. FB Thoren AI Romero M Brune, et al. 2009 Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia Expert Opin Biol Ther 9 1217 1223
19. HJ Pegram DM Andrews MJ Smyth, et al. 2011 Activating and inhibitory receptors of natural killer cells Immunol Cell Biol 89 216 224
20. MA Cheever JP Allison AS Ferris, et al. 2009 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337
21. L Chan NR Hardwick BA Guinn, et al. 2006 An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia Cancer Immunol Immunother 55 1017 1024 (Pubitemid 43673593)
22. O Bruserud E Ulvestad S Berentsen, et al. 1998 T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation Scand J Immunol 47 54 62 (Pubitemid 28057352)
23. D Behl LF Porrata SN Markovic, et al. 2006 Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia Leukemia 20 29 34
24. AJ Barrett BN Savani 2009 Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 23 53 58
25. C Scheibenbogen A Letsch E Thiel, et al. 2002 CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood 100 2132 2137 (Pubitemid 35001248)
26. J Greiner L Li M Ringhoffer TF Barth, et al. 2005 Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia Blood 106 938 945 (Pubitemid 41076438)
27. K Rezvani JM Brenchley DA Price, et al. 2005 T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization Clin Cancer Res 11 8799 8807 (Pubitemid 43005931)
28. Y Oka OA Elisseeva A Tsuboi, et al. 2000 Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product Immunogenetics 51 99 107 (Pubitemid 30150969)
29. H Ohminami M Yasukawa S Fujita 2000 HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide Blood 95 286 293 (Pubitemid 30017254)
30. K Rezvani 2008 PR1 vaccination in myeloid malignancies Expert Rev Vaccines 7 867 875
31. J Greiner M Schmitt L Li, et al. 2006 Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches Blood 108 4109 4117 (Pubitemid 44913282)
32. J Greiner H Dohner M Schmitt 2006 Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens Haematologica 91 1653 1661 (Pubitemid 46039635)
33. BA Guinn K Tobal KI Mills 2007 Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia Br J Haematol 136 510 512 (Pubitemid 46046311)
34. BA Guinn A Mohamedali KI Mills, et al. 2007 Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia Biomark Insights 2 69 79
35. J Greiner L Bullinger BA Guinn, et al. 2008 Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells Clin Cancer Res 14 7161 7166
36. J Greiner M Schmitt 2008 Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia Eur J Haematol 80 461 468 (Pubitemid 351677457)
37. BA Guinn L Bullinger NS Thomas, et al. 2008 SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients Br J Haematol 140 250 251 (Pubitemid 350265039)
38. C Yee JA Thompson P Roche, et al. 2000 Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo J Exp Med 192 1637 1644
39. Y Oka A Tsuboi T Taguchi, et al. 2004 Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc Natl Acad Sci USA 101 13885 13890 (Pubitemid 39298502)
40. Y Oka H Sugiyama 2010 WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects Immunotherapy 2 591 594
41. O Bruserud E Ulvestad 2000 Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation Cell Immunol 206 36 50 (Pubitemid 32105809)
42. O Bruserud 1999 Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies Leukemia 13 1175 1187 (Pubitemid 29396577)
43. AM Olsnes D Motorin A Ryningen, et al. 2006 T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC) Cancer Immunol Immunother 55 830 840
44. O Bruserud A Ryningen AM Olsnes, et al. 2007 Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells Haematologica 92 332 341 (Pubitemid 350143542)
45. O Bruserud S Frostad B Foss 1999 In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media J Hematother 8 63 73 (Pubitemid 29124992)
46. O Bruserud BT Gjertsen HL von Volkman 2000 In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines J Hematother Stem Cell Res 9 923 932 (Pubitemid 32110293)
47. O Bruserud E Ulvestad 1999 Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation J Hematother Stem Cell Res 8 431 441
48. RL Powles LA Balchin GH Fairley, et al. 1971 Recognition of leukaemia cells as foreign before and after autoimmunization Br Med J 1 486 489
49. RL Powles J Russell TA Lister, et al. 1977 Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient Br J Cancer 35 265 272 (Pubitemid 8057356)
50. WG Zhang SH Liu XM Cao, et al. 2005 A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6 Leuk Res 29 3 9
51. VF Van Tendeloo C Van Broeckhoven ZN Berneman 2001 Gene-based cancer vaccines: an ex vivo approach Leukemia 15 545 558 (Pubitemid 32273135)
52. A Cignetti A Guarini A Carbone, et al. 1994 Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression J Natl Cancer Inst 86 785 791 (Pubitemid 24152895)
53. U Matulonis C Dosiou G Freeman, et al. 1996 B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct J Immunol 156 1126 1131 (Pubitemid 26048107)
54. Y Nakazaki K Tani ZT Lin, et al. 1998 Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity Gene Ther 5 1355 1362 (Pubitemid 28482663)
55. K Dunussi-Joannopoulos G Dranoff HJ Weinstein, et al. 1998 Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines Blood 91 222 230 (Pubitemid 28018748)
56. K Dunussi-Joannopoulos HJ Weinstein PW Nickerson, et al. 1996 Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML Blood 87 2938 2946 (Pubitemid 26102245)
57. T Mutis E Schrama CJ Melief, et al. 1998 CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens Blood 92 1677 1684 (Pubitemid 28406872)
58. F Schakowski P Buttgereit M Mazur, et al. 2004 Novel non-viral method for transfection of primary leukemia cells and cell lines Genet Vaccines Ther 2 1
59. WJ Hirst A Buggins D Darling, et al. 1997 Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1 Gene Ther 4 691 699 (Pubitemid 27343131)
60. PH Roddie T Paterson ML Turner 2000 Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines Cytokines Cell Mol Ther 6 127 134 (Pubitemid 32098585)
61. E Wattel M Vanrumbeke MA Abina, et al. 1996 Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies Leukemia 10 171 174 (Pubitemid 26052997)
62. DS Howard DA Rizzierri B Grimes, et al. 1999 Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer Leukemia 13 1608 1616 (Pubitemid 29465624)
63. A Saudemont S Corm T Wickham, et al. 2005 Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha Mol Ther 11 950 959 (Pubitemid 40724114)
64. D Dilloo D Rill C Entwistle, et al. 1997 A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells Blood 89 119 127 (Pubitemid 26428185)
65. R Anderson I Macdonald T Corbett, et al. 1997 Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus Hum Gene Ther 8 1125 1135 (Pubitemid 27308210)
66. R Gonzalez R Vereecque TJ Wickham, et al. 1999 Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein Gene Ther 6 314 320 (Pubitemid 29132334)
67. R Stripecke AA Cardoso KA Pepper, et al. 2000 Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses Blood 96 1317 1326 (Pubitemid 30658459)
68. E Biagi F Bambacioni G Gaipa, et al. 2001 Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells Haematologica 86 13 16 (Pubitemid 32147044)
69. RC Koya N Kasahara V Pullarkat, et al. 2002 Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses Leukemia 16 1645 1654
70. NK Heinzinger MI Bukinsky SA Haggerty, et al. 1994 The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells Proc Natl Acad Sci USA 91 7311 7315 (Pubitemid 24226853)
71. RC Koya JS Weber N Kasahara, et al. 2004 Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro Hum Gene Ther 15 733 748 (Pubitemid 39095246)
72. J Gaken J Jiang K Daniel, et al. 2000 Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron Gene Ther 7 1979 1985 (Pubitemid 32036762)
73. L Chan N Hardwick D Darling, et al. 2005 IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML Mol Ther 11 120 131 (Pubitemid 40012006)
74. W Ingram L Chan H Guven, et al. 2009 Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study Br J Haematol 145 749 760
75. N Hardwick L Chan W Ingram, et al. 2010 Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80 Cancer Immunol Immunother 59 379 388
76. IM Borrello HI Levitsky W Stock, et al. 2009 Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML) Blood 114 1736 1745
77. D Koos SF Josephs DT Alexandrescu, et al. 2010 Tumor vaccines in 2010: need for integration Cell Immunol 263 138 147
78. EL Smits P Ponsaerts AL Van de Velde, et al. 2007 Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells Leukemia 21 1691 1699 (Pubitemid 47086759)
79. T Kawai S Akira 2010 The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 373 384
80. GP Dunn CM Koebel RD Schreiber 2006 Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 836 848 (Pubitemid 44631652)
81. M Ferrantini I Capone F Belardelli 2007 Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use Biochimie 89 884 893 (Pubitemid 47001642)
82. E Lion EL Smits ZN Berneman, et al. 2009 Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells Leuk Res 33 539 546
83. E Lion EL Smits ZN Berneman, et al. 2009 Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays J Immunol Methods 350 89 96
84. EL Smits N Cools E Lion, et al. 2010 The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells Cancer Immunol Immunother 59 35 46
85. AM Olsnes KJ Hatfield O Bruserud 2009 The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia J BUON 14 S131 S140
86. AM Olsnes A Ryningen E Ersvaer, et al. 2008 In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22 J Interferon Cytokine Res 28 297 310 (Pubitemid 351725302)
87. R Le Dieu DC Taussig AG Ramsay, et al. 2009 Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Blood 114 18 3909 3916
88. MJ Szczepanski M Szajnik M Czystowska, et al. 2009 Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia Clin Cancer Res 15 10 3325 3332
89. N Cools P Ponsaerts VF Van Tendeloo, et al. 2007 Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J Leukoc Biol 82 1365 1374 (Pubitemid 350276946)
90. NC Robson S Hoves E Maraskovsky, et al. 2010 Presentation of tumour antigens by dendritic cells and challenges faced Curr Opin Immunol 22 137 144
91. EL Smits S Anguille N Cools, et al. 2009 Dendritic cell-based cancer gene therapy Hum Gene Ther 20 1106 1118
92. N Romani S Gruner D Brang, et al. 1994 Proliferating dendritic cell progenitors in human blood J Exp Med 180 83 93 (Pubitemid 24181058)
93. RM Steinman J Banchereau 2007 Taking dendritic cells into medicine Nature 449 419 426 (Pubitemid 47509552)
94. S Anguille EL Smits N Cools, et al. 2009 Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties J Transl Med 7 109
95. RE Brouwer M van der Hoorn HC Kluin-Nelemans, et al. 2000 The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses Hum Immunol 61 565 574 (Pubitemid 30346483)
96. L Li P Reinhardt A Schmitt, et al. 2005 Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens Cancer Immunol Immunother 54 685 693 (Pubitemid 40884165)
97. C Hicks C Cheung R Lindeman 2003 Restimulation of tumour-specific immunity in a patient with AML following injection with B7-1 positive autologous blasts Leuk Res 27 1051 1061 (Pubitemid 36809076)
98. I Houtenbos TM Westers GJ Ossenkoppele, et al. 2006 Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia Immunobiology 211 677 685
99. L Li K Giannopoulos P Reinhardt, et al. 2006 Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts Int J Oncol 28 855 861
100. H Roddie M Klammer C Thomas, et al. 2006 Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia Br J Haematol 133 152 157
101. I Houtenbos TM Westers GJ Ossenkoppele, et al. 2006 Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia Br J Haematol 134 445 446 (Pubitemid 44079559)
102. A Kremser J Dressig C Grabrucker, et al. 2010 Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods J Immunother 33 185 199
103. C Grabrucker A Liepert J Dreyig, et al. 2010 The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells J Immunother 33 523 537
104. A Liepert C Grabrucker A Kremser 2010 Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential Cell Immunol 265 23 30
105. Y Osman M Takahashi Z Zheng, et al. 1999 Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy J Exp Clin Cancer Res 18 485 492 (Pubitemid 30114737)
106. M Zeis S Siegel A Wagner, et al. 2003 Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells J Immunol 170 5391 5397 (Pubitemid 36617824)
107. VF Van Tendeloo A Van de Velde A Van Driessche, et al. 2010 Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination Proc Natl Acad Sci USA 107 13824 13829
108. S Fujii K Fujimoto K Shimizu, et al. 1999 Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients Cancer Res 59 2150 2158 (Pubitemid 29217679)
109. J Galea-Lauri D Darling G Mufti, et al. 2002 Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination Cancer Immunol Immunother 51 299 310 (Pubitemid 34743982)
110. R Spisek P Chevallier N Morineau, et al. 2002 Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin Cancer Res 62 2861 2868 (Pubitemid 34525772)
111. GA Banat N Usluoglu M Hoeck, et al. 2004 Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes Br J Haematol 126 593 601 (Pubitemid 39093103)
112. JJ Lee H Kook MS Park, et al. 2004 Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation J Clin Apher 19 66 70 (Pubitemid 39006610)
113. M Klammer M Waterfall K Samuel, et al. 2005 Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia Br J Haematol 129 340 349 (Pubitemid 40646892)
114. JJ Lee MS Park JS Park, et al. 2006 Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens J Clin Apher 21 188 194
115. A Van Driessche AL Van de Velde G Nijs, et al. 2009 Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial Cytotherapy 11 653 668
116. AO Cavdar E Babacan S Gozdasoglu, et al. 1993 T-lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): a preliminary study Med Oncol Tumor Pharmacother 10 113 115 (Pubitemid 23290562)
117. O Bruserud 2000 Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells Int J Immunopharmacol 22 69 81 (Pubitemid 30102262)
118. RT Costello S Sivori E Marcenaro, et al. 2002 Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia Blood 99 3661 3667 (Pubitemid 34534536)
119. C Fauriat A Moretta D Olive, et al. 2005 Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients Blood 106 2186 2188 (Pubitemid 41291738)
120. P Nowbakht MC Ionescu A Rohner, et al. 2005 Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias Blood 105 3615 3622 (Pubitemid 40628208)
121. C Fauriat S Just-Landi F Mallet, et al. 2007 Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction Blood 109 323 330 (Pubitemid 46053073)
122. JJ Molldrem 2006 Vaccination for leukemia Biol Blood Marrow Transplant 12 13 18 (Pubitemid 43034114)
123. Heslop HE, Stevenson FK, Molldrem JJ (2003) Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 331-349
124. Schmid C, Labopin M, Nagler A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25:4938-4945 (Pubitemid 350225492)
125. ZA Yegin ZN Ozkurt SZ Aki, et al. 2010 Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation Transfus Apher Sci 42 239 245
126. B Gesundheit MY Shapira IB Resnick, et al. 2009 Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation Am J Hematol 84 188 190
127. JG Gribben EC Guinan VA Boussiotis, et al. 1996 Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool Blood 87 4887 4893
128. CP Larsen ET Elwood DZ Alexander, et al. 1996 Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways Nature 381 434 438 (Pubitemid 26162734)
129. BR Blazar PA Taylor A Panoskaltsis-Mortari, et al. 1997 Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation J Immunol 158 29 39 (Pubitemid 127483838)
130. EC Guinan VA Boussiotis D Neuberg, et al. 1999 Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1704 1714 (Pubitemid 29252598)
131. M Cavazzana-Calvo C Fromont F Le Deist, et al. 1990 Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin Transplantation 50 1 7 (Pubitemid 20221789)
132. D Valteau-Couanet M Cavazzana-Calvo F Le Deist, et al. 1993 Functional study of residual T lymphocytes after specific elimination of alloreactive T cells by a specific anti-interleukin-2 receptor Bk chain immunotoxin Transplantation 56 1574 1576 (Pubitemid 24018836)
133. DT Harris D Sakiestewa C Lyons, et al. 1999 Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor Bone Marrow Transplant 23 137 144 (Pubitemid 29048214)
134. D Montagna E Yvon V Calcaterra, et al. 1999 Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity Blood 93 3550 3557 (Pubitemid 29220923)
135. AM van Dijk FL Kessler SA Stadhouders-Keet, et al. 1999 Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease Br J Haematol 107 169 175 (Pubitemid 29500823)
136. I Andre-Schmutz F Le Deist S Hacein-Bey-Abina, et al. 2002 Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study Lancet 360 130 137 (Pubitemid 34786202)
137. MB Koh HG Prentice M Corbo, et al. 2002 Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment Br J Haematol 118 108 116 (Pubitemid 34779522)
138. SR Solomon S Mielke BN Savani, et al. 2005 Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation Blood 106 1123 1129 (Pubitemid 41076463)
139. TC Wehler M Nonn B Brandt, et al. 2007 Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines Blood 109 365 373 (Pubitemid 46053079)
140. X Ge J Brown M Sykes, et al. 2008 CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors Biol Blood Marrow Transplant 14 518 530 (Pubitemid 351494743)
141. UF Hartwig M Nonn S Khan, et al. 2008 Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity Biol Blood Marrow Transplant 14 99 109 (Pubitemid 350286744)
142. M Nonn W Herr S Khan, et al. 2008 Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering Transplantation 86 1427 1435
143. E Marijt A Wafelman M van der Hoorn, et al. 2007 Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation Haematologica 92 72 80 (Pubitemid 46232660)
144. GA Colvin D Berz M Ramanathan, et al. 2009 Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism Biol Blood Marrow Transplant 15 421 431
145. A Eljaafari A Farre K Duperrier, et al. 2001 Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells Transplantation 71 1449 1455 (Pubitemid 32507120)
146. T Azuma M Makita K Ninomiya, et al. 2002 Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes Br J Haematol 116 601 603 (Pubitemid 34178660)
147. JH Falkenburg WA Marijt MH Heemskerk, et al. 2002 Minor histocompatibility antigens as targets of graft-versus-leukemia reactions Curr Opin Hematol 9 497 502 (Pubitemid 35191118)
148. E Sadovnikova EN Parovichnikova VG Savchenko, et al. 2002 The CD68 protein as a potential target for leukaemia-reactive CTL Leukemia 16 2019 2026 (Pubitemid 35203444)
149. PJ Amrolia SD Reid L Gao, et al. 2003 Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity Blood 101 1007 1014 (Pubitemid 36139373)
150. T Mutis 2003 Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation Int J Hematol 78 208 212 (Pubitemid 37288506)
151. H Fujiwara F El Ouriaghli M Grube, et al. 2004 Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase Blood 103 3076 3083 (Pubitemid 38451684)
152. Y Guo H Niiya T Azuma, et al. 2005 Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner Blood 106 1415 1418 (Pubitemid 41129609)
153. T Tsuji M Yasukawa J Matsuzaki, et al. 2005 Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes Blood 106 470 476 (Pubitemid 40981240)
154. SA Xue L Gao D Hart, et al. 2005 Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells Blood 106 3062 3067 (Pubitemid 41565901)
155. WY Ho HN Nguyen M Wolfl, et al. 2006 In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire J Immunol Methods 310 40 52 (Pubitemid 43375974)
156. MH Heemskerk 2010 T-cell receptor gene transfer for the treatment of leukemia and other tumors Haematologica 95 15 19
157. Ochi T, Fujiwara H, Yasukawa M (2010) Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia. J Biomed Biotechnol 521248
158. JF Vera MK Brenner G Dotti 2009 Immunotherapy of human cancers using gene modified T lymphocytes Curr Gene Ther 9 396 408
159. SA Xue L Gao S Thomas 2010 Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice Haematologica 95 126 134
160. S Peinert HM Prince PM Guru, et al. 2010 Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen Gene Ther 5 678 686
161. CH Lamers S Sleijfer AG Vulto, et al. 2006 Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 e20 e22
162. R Brentjens R Yeh Y Bernal, et al. 2010 Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 666 668
163. R Mohle F Bautz S Rafii, et al. 1998 The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1 Blood 91 4523 4530 (Pubitemid 28270300)
164. M Bleakley SR Riddell 2004 Molecules and mechanisms of the graft-versus-leukaemia effect Nat Rev Cancer 4 371 380 (Pubitemid 38579483)
165. L Ruggeri F Aversa MF Martelli, et al. 2006 Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self Immunol Rev 214 202 218 (Pubitemid 44707912)
166. I Waldhauer A Steinle 2008 NK cells and cancer immunosurveillance Oncogene 27 5932 5943
167. SS Farag TA Fehniger L Ruggeri, et al. 2002 Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect Blood 100 1935 1947 (Pubitemid 35001221)
168. L Ruggeri M Capanni E Urbani 2002 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2097 2100 (Pubitemid 34229476)
169. W Leung R Iyengar V Turner, et al. 2004 Determinants of antileukemia effects of allogeneic NK cells J Immunol 172 644 650 (Pubitemid 38020523)
170. S Verheyden C Demanet 2008 NK cell receptors and their ligands in leukemia Leukemia 22 249 257 (Pubitemid 351250528)
171. JS Miller Y Soignier A Panoskaltsis-Mortari, et al. 2005 Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051 3057
172. JE Rubnitz H Inaba RC Ribeiro, et al. 2010 NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 955 959
173. D Cho D Campana 2009 Expansion and activation of natural killer cells for cancer immunotherapy Korean J Lab Med 29 89 96
174. U Siegler S Meyer-Monard S Jorger, et al. 2010 Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients Cytotherapy 12 750 763
175. U Koehl J Sorensen R Esser, et al. 2004 IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation Blood Cells Mol Dis 33 261 266 (Pubitemid 39446496)
176. MJ Robertson 2002 Role of chemokines in the biology of natural killer cells J Leukoc Biol 71 173 183
177. O Bruserud AO Kittang 2010 The chemokine system in experimental and clinical hematology Curr Top Microbiol Immunol 341 3 12
178. AA Maghazachi 2010 Role of chemokines in the biology of natural killer cells Curr Top Microbiol Immunol 341 37 58
179. I Muller S Kordowich C Holzwarth, et al. 2008 Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation Blood Cells Mol Dis 40 25 32 (Pubitemid 350199635)
180. N Meuleman T Tondreau I Ahmad, et al. 2009 Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study Stem Cells Dev 18 1247 1252
181. C Gotherstrom A Lundqvist IR Duprez, et al. 2011 Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways Cytotherapy 13 269 278
182. E Klyuchnikov S Asenova W Kern, et al. 2010 Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia Leuk Lymphoma 51 1450 1463
183. S Gross P Walden 2010 Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer Immunol Lett 116 7 14
184. SA Rosenberg NP Restifo JC Yang, et al. 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 299 308 (Pubitemid 351430867)
185. EL Smits P Ponsaerts ZN Berneman, et al. 2008 The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Oncologist 13 859 875
186. J Weber 2007 Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events Oncologist 12 864 872 (Pubitemid 47328229)